Adgero Biopharmaceuticals Holdings, Inc. - FORM S-1/A - EX-23.1 - CONSENT OF MARCUM LLP - October 16, 2017

Attached files

file filename
EX-10.35 - EMPLOYMENT AGREEMENT, DATED SEPTEMBER 1, 2017, BETWEEN THE COMPANY AND FELIX GAR - Adgero Biopharmaceuticals Holdings, Inc.adg_ex1035.htm
EX-10.34 - WARRANT AGENT AGREEMENT, DATED AUGUST 14, 2017, BETWEEN THE COMPANY AND AEGIS CA - Adgero Biopharmaceuticals Holdings, Inc.adg_ex1034.htm
EX-10.28 - EMPLOYMENT AGREEMENT, DATED OCTOBER 11, 2017, BETWEEN THE COMPANY AND JOHN LIATO - Adgero Biopharmaceuticals Holdings, Inc.adg_ex1028.htm
EX-4.8 - SECOND AMENDMENT OF REGISTRATION RIGHTS AGREEMENT - Adgero Biopharmaceuticals Holdings, Inc.adg_ex48.htm
S-1/A - AMENDMENT NO. 2 ON FORM S-1 - Adgero Biopharmaceuticals Holdings, Inc.adg_s1a.htm
Exhibit 23.1
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S CONSENT
 
We consent to the inclusion in this Registration Statement of Adgero Biopharmaceuticals Holdings, Inc. on Form S-1 Amendment No. 2 (File No. 333-216052) of our report dated April 11, 2017 with respect to our audits of the consolidated financial statements of Adgero Biopharmaceuticals Holdings, Inc. as of December 31, 2016 and 2015 and for each of the years then ended, which report appears in the Prospectus, which is part of this Registration Statement. We also consent to the reference to our Firm under the heading “Experts” in such Prospectus.
 
/s/ Marcum LLP
 
Marcum LLP
New York, NY
October 16, 2017